抗HBV治疗性疫苗联合拉米夫定治疗慢性HBV感染者的临床实验研究  

The Clinical of experimental study on anti-HBV therapeutic vaccine in the treatment of chronic HBV infector

作　　者：江勇 冯耀芳 

机构地区：[1]福建省福州福兴医院,350014

出　　处：《中国实用医药》2007年第35期3-4,共2页China Practical Medicine

摘　　要：目的进一步验证抗HBV治疗性疫苗联合拉米夫定治疗慢性HBV感染者的临床疗效。方法确诊为慢性HBV感染者520例患者随机分为实验组260例,用抗HBV治疗性疫苗,1次/月,皮下注射,同时联合口服拉米夫定100mg/d,疗程为12个月;对照组260例,单纯口服拉米夫定100mg/d,疗程为12个月。检测血清HBsAg、HBeAg、HBVDNA、抗-HBe、抗-HBs及ALT。结果实验组HBsAg、HBeAg、HBVDNA阴转率及抗-HBe、抗-HBs阳转率分别为25.4%、45.0%、53.5%、30.4%、14.6%;对照组分别为11.9%、22.3%、28.1%、9.6%、2.7%,两组相比差异有统计学意义(P<0.05)。结论抗HBV治疗性疫苗联合拉米夫定对慢性HBV感染者有较好的临床疗效。Objective To farther prove the clinical efficacy of anti-HBV therapeutic vaccine in the treatment of chronic HBV infector.Methods 520 patients diagnosed as chronic HBV infector based on the criteria formulated by the guide of prophylaxis and treatment to chronic hepatitis B were randomly assigned into two groups.The treated group with 260 cases was treated by anti-HBV therapeutic vaccine once every month,subcutaneous injection-plus lamivudine 100mg/day p.o.for 12 months; the controlled group with 260 cases was treated only by lamivudine 100mg/day p.o.for 12 months.Serum HBsAg,HBeAg,HBV DNA,anti-HBe,anti-HBs and ALT were detected.Results The seronegative rate of serum HBsAg,HBeAg and HBV DNA of the treated group were 25.4%,45.0% and 53.5% respectively,the seroconvertion of serum HBeAg to anti-HBe and HBsAg to anti-HBs were 30.4%,14.6%. The controlled group was 11.9%,22.3%,28.1%,9.6%,2.7% repectively,there are obvious differences between them,P<0.05.Conclusion Anti-HBV therapeutic vaccine plus lamivudine show a certain extent clinical efficacy.

关 键 词：乙型肝炎 疫苗 主动免疫疗法 拉米夫定 慢乙型肝炎 

分 类 号：R512.62[医药卫生—内科学]